Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 10/3/2025

Dietary Recommendations for GLP-1 Weight Loss Treatments

Introduction to GLP-1 Therapy

  • The American Diabetes Association recommends a hypocaloric diet with at least a 500 kcal daily deficit below total energy requirements, combined with 150 minutes per week of physical activity, while gradually titrating GLP-1 receptor agonists to minimize gastrointestinal side effects 1, 2, 3

Core Dietary Structure

  • Implement a structured caloric deficit of 500-1000 kcal below daily requirements to optimize weight loss outcomes when combined with GLP-1 therapy, as recommended by the Gastroenterology society 4
  • Prioritize protein intake to preserve lean body mass, as GLP-1s can cause muscle loss alongside fat loss, according to the American College of Cardiology 5

Macronutrient Distribution

  • Substitute foods higher in unsaturated fats for those higher in trans or saturated fats to improve cardiovascular risk profile, as suggested by the American Heart Association 1, 3
  • Select leaner protein sources and meat alternatives to reduce saturated fat intake, as recommended by the American Diabetes Association 1, 3
  • Moderate carbohydrate intake at each meal if taking GLP-1s alongside insulin secretagogues to reduce hypoglycemia risk, according to the Endocrine Society 1, 2, 3

Sodium and Alcohol Guidelines

  • Limit sodium intake to 2,300 mg per day, as recommended by the American Heart Association 1, 2, 3
  • Moderate alcohol consumption (one drink/day or less for women, two drinks/day or less for men) has minimal effects on blood glucose, but alcohol should be consumed with food if taking insulin or insulin secretagogues, according to the National Institute on Alcohol Abuse and Alcoholism 1, 2

Managing Gastrointestinal Side Effects Through Diet

  • Gradual dose titration is essential to minimize nausea, vomiting, and diarrhea, which are the most common side effects of GLP-1 therapy, as recommended by the American Gastroenterological Association 1, 2, 3, 4, 5
  • Take medication with food or 15 minutes after a meal if gastrointestinal symptoms persist during titration, as suggested by the American Diabetes Association 1, 2

Preventing Nutritional Deficiencies

  • Do not use vitamin and mineral supplements, herbal products, or cinnamon specifically to manage diabetes, as there is lack of evidence for their efficacy, according to the National Institutes of Health 1, 3
  • Ensure adequate protein intake to minimize loss of lean body mass, which occurs alongside fat loss, as recommended by the Academy of Nutrition and Dietetics 5, 6

Physical Activity Integration

  • Combine GLP-1 therapy with 150 minutes per week of physical activity, emphasizing resistance training to preserve lean body mass, as recommended by the American College of Sports Medicine 4, 5
  • Resistance training is critical to prevent muscle loss that occurs with GLP-1-induced weight reduction, according to the National Academy of Sciences 5, 6

Special Considerations for Concurrent Diabetes Medications

  • Eat a source of carbohydrates at each meal to reduce hypoglycemia risk if taking GLP-1s with insulin secretagogues or insulin, as recommended by the American Diabetes Association 1, 2, 3
  • Do not skip meals, as this increases hypoglycemia risk, according to the Endocrine Society 1, 2, 3

Long-Term Dietary Maintenance

  • GLP-1 medications must be used long-term in conjunction with sustained lifestyle changes, as cessation leads to significant weight regain, as recommended by the American Heart Association 5, 7
  • Continue the hypocaloric diet and exercise program throughout GLP-1 treatment to maintain weight loss, according to the Academy of Nutrition and Dietetics 5, 7
  • Increased risk of gallbladder disease requires vigilance for symptoms, as recommended by the American Gastroenterological Association 4, 5, 7
  • Contraindicated in patients with personal or family history of medullary thyroid cancer or multiple endocrine neoplasia syndrome type 2, according to the National Cancer Institute 4, 5, 6, 7